Jardiance Employer + ICHRA Coverage Navigation: How to Get Empagliflozin Cheaper in 2026

What Is Jardiance and Why Does Coverage Matter?

Jardiance is the brand name for empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA in 2014 for type 2 diabetes and subsequently for heart failure and chronic kidney disease (CKD). [1] [2] Because it carries multiple FDA indications, coverage decisions depend heavily on which diagnosis code your prescriber submits and which tier your plan places the drug on.

The Clinical Case for Coverage

The evidence base for empagliflozin is unusually strong. The EMPA-REG OUTCOME trial (N=7,020) showed a 38% relative risk reduction in cardiovascular (CV) death among patients with type 2 diabetes and established CV disease taking empagliflozin versus placebo. [3] The EMPEROR-Reduced trial (N=3,730) found empagliflozin reduced the composite of CV death or heart-failure hospitalization by 25% relative to placebo in patients with heart failure and reduced ejection fraction (HFrEF). [4] The EMPEROR-Preserved trial (N=5,988) extended that benefit to heart failure with preserved ejection fraction (HFpEF), a population with historically few pharmacologic options. [5]

Payers recognize these outcomes. The American Diabetes Association 2024 Standards of Care recommend SGLT2 inhibitors with proven CV benefit for patients with type 2 diabetes and atherosclerotic cardiovascular disease, heart failure, or CKD regardless of HbA1c. [6]

Why List Price Alone Is Misleading

The wholesale acquisition cost (WAC) for Jardiance runs approximately $650, $690 for a 30-day supply in 2026. That number drives understandable alarm. But the net price after insurance negotiation and manufacturer rebates is substantially lower, and the savings card program (discussed below) applies on top of insurance discounts for commercially insured patients.

Employer-Sponsored Plan Coverage: What to Expect

Most large employer-sponsored plans cover Jardiance. The path to a manageable copay typically involves tier placement, prior authorization (PA), and sometimes step therapy.

Tier Placement

Commercial plans generally place Jardiance on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). A 2023 analysis of commercial formularies found SGLT2 inhibitors listed on Tier 3 or higher in roughly 80% of large-group plans. [7] Tier 3 copays average $50, $100 per month before any savings card; Tier 4 copays can exceed $150. Your Summary of Benefits and Coverage (SBC) document, available from HR or your insurer's portal, shows your plan's exact tier structure.

Prior Authorization Requirements

Employer plans almost universally require PA for Jardiance. The PA criteria typically ask for:

• A confirmed diagnosis of type 2 diabetes, HFrEF, HFpEF, or CKD stages 2 to 4
• An HbA1c result (for diabetes indications, usually HbA1c above 7.0%)
• Documentation that metformin was tried first, or a contraindication to metformin
• For the CKD indication, a documented eGFR of 20 to 45 mL/min/1.73 m² (per DAPA-CKD and EMPA-KIDNEY data ranges) [8]

Your prescriber's office submits the PA. If denied, the plan is required to provide a written reason and inform you of appeal rights under the Employee Retirement Income Security Act (ERISA). [9]

Step Therapy and How to Overcome It

Some plans require a prior trial of a generic SGLT2 inhibitor (dapagliflozin is now generic) before approving Jardiance by brand. If your prescriber has a clinical reason to prefer empagliflozin specifically (e.g., the patient has already tried dapagliflozin or has a documented intolerance), that exception should be noted in the PA request. The ADA and American Heart Association joint guidelines state that the choice among SGLT2 inhibitors should be guided by individual CV and renal risk profiles. [10]

ICHRA and Jardiance: How the Math Works

An Individual Coverage Health Reimbursement Arrangement (ICHRA) lets employers reimburse employees tax-free for premiums and sometimes out-of-pocket costs on a Qualifying Health Plan (QHP) purchased in the individual or small-group market. Jardiance is not reimbursed directly by an ICHRA; the ICHRA funds the premium on a QHP that may cover Jardiance.

Choosing the Right QHP

When selecting a QHP through Healthcare.gov or a state exchange, search the plan's formulary before enrolling. Use the plan's drug search tool and look for empagliflozin or Jardiance. Plans sold on the ACA marketplaces must cover essential health benefits, which include prescription drugs, but formulary placement varies by insurer and metal level. [11] A Silver or Gold plan is more likely to carry Jardiance on a preferred tier than a Bronze plan, though Bronze plans are cheaper in premium.

The IRS Notice 2019-45 confirmed that ICHRA dollars are excluded from gross income when used for qualifying medical expenses, including QHP premiums. [12] For 2026, the IRS maximum ICHRA contribution from employers has no statutory cap; the employer sets the amount.

ICHRA + Savings Card Stacking

Here is a critical point many patients miss. The Boehringer Ingelheim/Lilly savings card is usable for commercially insured patients, including those enrolled in a QHP through an ICHRA. The card is not usable for Medicare, Medicaid, or CHIP beneficiaries. [13] If your ICHRA-linked QHP covers Jardiance at Tier 3, you pay the Tier 3 copay at the pharmacy and then the savings card applies, potentially reducing that copay to $10 per month.

The HealthRX Access Framework for ICHRA + Jardiance works in three steps. First, use your ICHRA dollars to select a QHP with Jardiance on Tier 2 or Tier 3 (not excluded). Second, obtain a PA through your prescriber using the appropriate ICD-10 code (E11.x for type 2 diabetes, I50.x for heart failure, N18.x for CKD). Third, activate the Boehringer Ingelheim/Lilly savings card at jardiance.com/savings and present it alongside your insurance card at the pharmacy.

The Boehringer Ingelheim and Lilly Jardiance Savings Card

The manufacturer savings program is the most direct way to reduce out-of-pocket cost for commercially insured patients. As of 2026, eligible patients can pay as little as $10 per month using the card, with a maximum annual savings cap that has historically been set at $3,500 per calendar year.

Eligibility Rules

• Must have commercial insurance (employer-sponsored or individual/ICHRA-linked QHP)
• Not eligible if primary payer is Medicare Part D, Medicaid, CHIP, VA, or TRICARE
• Must be a U.S. Resident age 18 or older
• Prescription must be for an FDA-approved indication [14]

Activation Steps

1. Visit jardiance.com/savings or ask your pharmacist to activate the card on your behalf.
2. Provide your insurance information. The card works as a secondary payer at the point of sale.
3. Present both cards at every pharmacy fill. The process is electronic; no paper card is required at most major pharmacy chains.

If the pharmacy cannot process the card, call the BenefitCenter number printed on the card. Specialty and mail-order pharmacies may require manual processing.

HSA and FSA Eligibility for Jardiance

Jardiance is an FDA-approved prescription drug, which means it qualifies as a medical expense under IRS Publication 502. [15] Both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can be used to pay Jardiance copays, coinsurance, or the full cash price if you are uninsured or in a high-deductible phase.

HSA-Specific Rules

To contribute to an HSA in 2026, you must be enrolled in a High-Deductible Health Plan (HDHP) with a minimum deductible of $1,650 (self-only) or $3,300 (family), per IRS Rev. Proc. 2025-19. [16] The HSA contribution limit for 2026 is $4,300 (self-only) or $8,550 (family). Using HSA dollars for Jardiance is straightforward: pay at the pharmacy with your HSA debit card or submit for reimbursement.

FSA Considerations

FSAs are use-it-or-lose-it within the plan year (with a grace period or $640 rollover in plans that permit it). If you are filling Jardiance monthly, scheduling refills before the FSA deadline ensures you use those dollars efficiently. Annual Jardiance spend at a typical Tier 3 copay of $70/month is $840 per year before any savings card, which fits comfortably within a standard FSA election.

Medicare Part D and the Coverage Gap

Employees who are 65 or older and covered by an employer plan that is primary to Medicare can still use the Jardiance savings card as long as they are NOT using Medicare Part D as the primary payer. This is a common point of confusion for employees who are Medicare-eligible but remain on an employer plan.

Once Medicare Part D becomes the primary drug benefit, the savings card is no longer usable. [17] At that point, the Low-Income Subsidy (LIS/Extra Help) program and the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D (effective 2025) become the primary cost-reduction tools. [18]

Generic Empagliflozin: Current Status

As of mid-2025, branded Jardiance remains under patent protection in the United States. Boehringer Ingelheim holds patents on the compound and formulation that are not expected to expire until the late 2020s. The FDA's Orange Book lists the relevant patents; no generic application has received tentative approval for 10 mg or 25 mg empagliflozin tablets as of the date of this article. [19] Patients should verify current status at accessdata.fda.gov before assuming a generic is available.

Prior Authorization Appeal Strategy

A denied PA is not the end of the road. Under ERISA, employer plan members have the right to a full and fair review of any adverse benefit determination within 180 days of the denial. [9] The appeal should include:

• A letter of medical necessity from the prescribing physician
• Copies of relevant trial data (EMPA-REG OUTCOME, EMPEROR-Reduced, EMPA-KIDNEY) [3] [4] [20]
• ADA Standards of Care guideline text recommending SGLT2 inhibitors for the patient's diagnosis [6]
• Documentation of any contraindications to required step-therapy alternatives

If the internal appeal fails, patients in employer-sponsored plans subject to ERISA may request an external review. The Affordable Care Act mandates access to independent external review for non-grandfathered plans. [21]

Peer-to-Peer Review

The most effective tool when time is limited is a peer-to-peer (P2P) call between the prescriber and the plan's medical director. Studies of P2P reviews in oncology suggest overturnal rates above 50% when the prescriber participates directly. [22] The same dynamic applies to cardiometabolic drugs with strong outcomes data. Ask your prescriber's office specifically to request a P2P rather than relying solely on a written appeal.

State-Specific Protections

Several states have enacted SGLT2-specific or diabetes-drug cost-sharing caps. California, Colorado, and New York have enacted legislation limiting insulin and certain non-insulin diabetes drug cost-sharing for state-regulated plans, though ERISA self-funded employer plans are exempt from state mandates. [23] Check your state insurance commissioner's website to confirm whether your plan type is subject to state protections.

Manufacturer Patient Assistance Program

For patients without any insurance coverage, Boehringer Ingelheim offers the BI Cares Foundation patient assistance program. Eligibility is income-based, generally requiring household income at or below 400% of the federal poverty level. Applications are submitted through the prescriber's office or directly at biopharma.boehringer-ingelheim.com. Processing typically takes 2 to 4 weeks. [24]

GoodRx and similar pharmacy discount platforms list cash prices for empagliflozin at major pharmacy chains. As of mid-2025, GoodRx prices for 30 tablets of empagliflozin 10 mg ranged from $580 to $650 at retail chains without insurance, underscoring why the savings card or assistance program is essential for uninsured patients. [25]

Combining Strategies: A Step-by-Step Access Checklist

The table below summarizes which cost-reduction tools stack with each other and which are mutually exclusive.

| Coverage Situation | Savings Card | HSA/FSA | PA Required | Notes | |---|---|---|---|---| | Employer plan (commercial) | Yes | Yes | Usually | Stacks with both | | ICHRA-linked QHP | Yes | Yes | Usually | Select QHP with Jardiance on formulary | | Medicare Part D primary | No | N/A (no HSA if on Medicare) | Yes | IRA $2,000 cap applies instead | | No insurance (cash pay) | No | Yes (FSA only if employed) | No | BI Cares for low income | | Medicaid | No | No | Yes | State PDL determines access |

Follow these steps in order:

1. Confirm your plan type (employer self-funded, fully insured, ICHRA-linked QHP, Medicare Part D).
2. Check the formulary for empagliflozin/Jardiance and note the tier.
3. Have your prescriber submit PA with the correct ICD-10 and supporting lab data.
4. Activate the savings card if you have commercial coverage.
5. Set up HSA or FSA payroll contributions to cover any remaining copay.
6. If denied, initiate internal appeal within 180 days, request P2P review.

For patients whose employer contributes $200 or more per month to an ICHRA, selecting a Gold-tier QHP with Jardiance at Tier 3 and stacking the savings card can reduce effective monthly cost to $10, the minimum under the current savings program. [13]